- Home
- BCV vs CTMX Comparison
BCV vs CTMX Comparison
Compare BCV & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCV
- CTMX
- Stock Information
- Founded
- BCV 1971
- CTMX 2008
- Country
- BCV United States
- CTMX United States
- Employees
- BCV N/A
- CTMX N/A
- Industry
- BCV Finance/Investors Services
- CTMX Biotechnology: Pharmaceutical Preparations
- Sector
- BCV Finance
- CTMX Health Care
- Exchange
- BCV Nasdaq
- CTMX Nasdaq
- Market Cap
- BCV 106.0M
- CTMX 85.3M
- IPO Year
- BCV N/A
- CTMX 2015
- Fundamental
- Price
- BCV $18.16
- CTMX $0.84
- Analyst Decision
- BCV
- CTMX Buy
- Analyst Count
- BCV 0
- CTMX 6
- Target Price
- BCV N/A
- CTMX $5.77
- AVG Volume (30 Days)
- BCV 26.3K
- CTMX 1.2M
- Earning Date
- BCV 01-01-0001
- CTMX 03-10-2025
- Dividend Yield
- BCV 8.13%
- CTMX N/A
- EPS Growth
- BCV N/A
- CTMX N/A
- EPS
- BCV N/A
- CTMX 0.16
- Revenue
- BCV N/A
- CTMX $126,617,000.00
- Revenue This Year
- BCV N/A
- CTMX $22.55
- Revenue Next Year
- BCV N/A
- CTMX N/A
- P/E Ratio
- BCV N/A
- CTMX $5.20
- Revenue Growth
- BCV N/A
- CTMX 33.66
- 52 Week Low
- BCV $14.09
- CTMX $0.79
- 52 Week High
- BCV $18.11
- CTMX $5.85
- Technical
- Relative Strength Index (RSI)
- BCV 54.14
- CTMX 33.95
- Support Level
- BCV $17.78
- CTMX $0.79
- Resistance Level
- BCV $18.03
- CTMX $1.17
- Average True Range (ATR)
- BCV 0.29
- CTMX 0.08
- MACD
- BCV 0.00
- CTMX -0.03
- Stochastic Oscillator
- BCV 63.44
- CTMX 13.16
About BCV Bancroft Fund Ltd.
Bancroft Fund Ltd is a diversified closed-end management company. It operates as a closed-ended equity mutual fund. The funds' main objective is to provide income and potential for capital appreciation. With the intent to achieve its objective, the company invests in convertible and equity securities. It invests across different industries such as Computer Software and Services, Energy and Utilities, Health Care among others.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.